All News

2021

March

Media Release / Mar 04, 2021

Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate

Read More
Media Release / Mar 02, 2021

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Read More

February

Media Release / Feb 26, 2021

Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing

Read More
Media Release / Feb 26, 2021

Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis

Read More
Media Release / Feb 17, 2021

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

Read More
Media Release / Feb 16, 2021

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Read More
Media Release / Feb 16, 2021

Novartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector pen

Read More
Media Release / Feb 11, 2021

Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics

Read More
Media Release / Feb 08, 2021

Novartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia

Read More

January

Media Release / Jan 29, 2021

Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More